Real World Study To Assess Effectiveness and Safety of Vemurafenib As Monotherapy In Patients With Unresectable Or Metastatic Melanoma Using Data From MELBASE

Trial Profile

Real World Study To Assess Effectiveness and Safety of Vemurafenib As Monotherapy In Patients With Unresectable Or Metastatic Melanoma Using Data From MELBASE

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Nov 2016 New trial record
    • 02 Nov 2016 Results of this study, presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top